The company said it will use the funds to commercialize its proteomic PromarkerD kidney disease test and launch an analytical testing service business.
The Copenhagen-based firm published the first public demonstration of its InBio Map protein interaction tool in a study released this week in Nature Methods.
According to Cedars Sinai Medical Center's Jennifer Van Eyk, mass spec-based proteomics' clinical potential is on the cusp of being realized.
In a recent study, the researchers demonstrated the ability of proteoform-dependent data acquisition software to broaden coverage in top-down experiments.
The company said this week that is has raised $36 million in funding, as it continues efforts to develop its Maverick platform for rapid testing in doctors' offices.
Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.
Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.
The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.